Biotie: nepicastat study in cocaine dependence completes

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

May 27, 2014 at 2:15 AM

Biotie: nepicastat study in cocaine dependence completes enrollment ahead of schedule - top-line data expected around end 2014

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 27 May 2014 at 9.00 a.m. Biotie: nepicastat study in cocaine dependence completes enrollment ahead of schedule - top-line data expected around end 2014 Biotie Therapies today announced that patient enrollment into the Phase 2 study investigating nepicastat for cocaine dependence has been completed ahead of schedule. The 11-week, 179-patient study is being conducted at 10 US clinics under a Collaborative Research and Development Agreement (CRADA) with the National Institute on Drug Abuse (NIDA) at the US National Institutes of Health. Top-line results from the study are expected around the end of 2014. "The extraordinary commitment that both NIDA and the trial investigators have shown for this program has helped the study exceed the already ambitious enrollment targets", commented Dr. Stephen Bandak, CMO of Biotie. "We look forward to completion of the clinical treatment phase and await the top-line results, scheduled to be available around year end, with great interest." Turku, 27 May 2014 Biotie Therapies Corp. Timo Veromaa President and CEO For further information, please contact: Dr. Stephen Bandak, Chief Medical Officer tel. +1 650 296 0946 (Pacific Time zone), stephen.bandak@biotie.com Virve Nurmi, Investor Relations Manager tel. +358 2 274 8900, virve.nurmi@biotie.com Distribution: NASDAQ OMX Helsinki Ltd Main Media www.biotie.com About nepicastat (SYN117) Nepicastat is an orally administered, potent and selective inhibitor of the enzyme dopamine beta-hydroxylase (DBH) which converts dopamine into norepinephrine. Like many other addictions, cocaine dependence is driven by dysregulation in the dopamine-reward system. Inhibition of DBH by nepicastat increases levels of dopamine, which may reduce craving for cocaine, and reduces the levels of norepinephrine, which may decrease the pleasurable responses to cocaine and the potential for stress-induced relapse following withdrawal. Nepicastat is currently in Phase 2 development for cocaine dependence. A previously completed placebo-controlled Phase 2a study in non-treatment seeking cocaine addicts showed that nepicastat had a favourable safety profile and was well tolerated when administered with cocaine. An 11-week Phase 2 safety and efficacy trial in 179 treatment seeking cocaine addicted patients, funded by the U.S. National Institute on Drug Abuse under a Collaborative Research and Development Agreement, has completed patient enrollment, and top-line results are expected around the end of 2014. Biotie retains full rights to nepicastat and will be able to use data from studies conducted with NIDA to support future potential regulatory submissions. About Biotie Biotie is a specialized drug development company focused on products for neurodegenerative and psychiatric disorders. For the past years, Biotie has successfully operated a strategy built around search, profile and partner. This has delivered Selincro (nalmefene) for alcohol dependence, which received European marketing authorization in February 2013 and is currently being rolled out across Europe by partner H. Lundbeck A/S, and tozadenant, a novel A2a antagonist which is transitioning into Phase 3 development for Parkinson's disease and for which Biotie holds exclusive, global rights. Biotie is actively developing its pipeline assets, including SYN120, a unique potent 5-HT6/5-HT2a dual antagonist for which Biotie expects to conduct a Phase 2 study in Alzheimer's disease; nepicastat, a selective inhibitor of dopamine beta hydroxylase which is currently in a Phase 2 study, fully funded by NIDA, for treatment seeking cocaine addicts; and BTT-1023, a monoclonal antibody targeting Vascular Adhesion Protein 1 for which Biotie intends to conduct a Phase 2 study in primary sclerosing cholangitis, a rare fibrotic disease of the liver. Biotie's shares are listed on NASDAQ OMX Helsinki. [HUG#1788634]

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

OSHA and NSC Forge Alliance to Prevent Worksite Tragedies

Forging Ahead With a Crucial Collaboration Ins, outs, ups, and downs—safety shouldn’t get lost in the shuffle, but it does. In steps the National Serious Injury and Fatality Prevention Alliance, a fresh partnership convened by OSHA with the National Safety Council—hop on board or get left behind mindsets. We’re talking about real, heads-down, hard-hitting actions...

Local Expertise in Real Estate: Key to Success?

Local Market Know-How: A Seller's Best Asset So you're thinking about selling your home in North Carolina, huh? Here's a tip—get yourself a local real estate pro who knows the ins and outs of your neighborhood like the back of their hand. Michael McCollum, a prominent voice from Reidsville, NC, highlights how crucial local expertise can be in navigating the widely...

EPR Fireworks, Schedule2.IT Enhance EMS Integration

Joining Forces for Effective EMS Management In a move that could shake up emergency medical services, EPR Fireworks has teamed up with Schedule2.IT to amp up integration. This Florida-based partnership is all about breaking down those bureaucratic firewalls between patient care and controlled substances tracking. They’re pushing for a seamless workflow, where crucial...

Crucial Insights for South GA Home Insurance Choices

Understanding the Insurance Jargon Here we go again, dealing with insurance gobbledygook that’s about as clear as mud to most of us. Homeowners in South Georgia are being urged to pay attention to the differences between replacement cost and actual cash value in their insurance policies. This ain't just legalese, folks—it's your protection when disaster strikes in our...

Superga and Pasqua's Unlikely Fashion-Vineyard Fusion

Superga and Pasqua: A Fusion of Fashion and Vineyards Here's one for the books: Superga, the storied Italian footwear maestro, teaming up with Pasqua Wines, straight out of Verona’s vineyard heartland. On the surface, it seems a rather odd coupling. One's got rubber soles; the other’s got corks. But they’ve pulled off a daring bedroom switch, creating a...

Medicare Payment Proposal Faces Doctor Backlash in D.C.

Why Same-Day Medicare Care Matters Imagine you're gasping for breath, struggling to find relief, and then being told to wait weeks for care. It's not just an inconvenience; it's a health hazard. This isn't some arbitrary tale—it's the gritty reality for folks relying on same-day care. A group of docs and advocates recently stormed Capitol Hill sounding the alarm about a...

Vortex Expands UK Reach with Torrent Acquisition Boost

Vortex's Ambitious UK Expansion A seasoned investor keen on infrastructure plays would find Vortex Companies’ latest move significant—not just another acquisition, but a realigned strategy for dominance as Britain braces for an infrastructure overhaul. With Torrent Drainage Services in their pocket, the Vortex Group plans to amp up its trenchless rehabilitation...

University of Phoenix Grads Shine in Job Readiness

University of Phoenix Graduates Proving Their Worth Dive straight into the world of University of Phoenix grads, and you're looking at some folks who seem to have the workplace game figured out. A fresh Harris Poll, done on behalf of the University itself, paints a rosy picture of these graduates from the eyes of those who actually supervise them. Turns out, managers are...

JennAir and Cosentino Introduce Seamless Kitchen Aesthetics

It's not every day that the kitchen landscape gets a bold makeover, but JennAir and Cosentino seem to think it's time. Introducing their latest splash, the JennAir x Dekton panel collection is here to redefine what luxury kitchens can look like—an embodiment of seamless beauty that’s more sculpture than cooking space. Elevating Kitchen Design So, what's the buzz about...

Roof Replacement Timelines: Key Insights for PA Homeowners

There's no denying it; having a roof over your head is one thing, but knowing when to replace it is a whole other ballgame. In Pennsylvania, where the weather loves to throw curveballs, making the right call on roof replacement can save a heap of trouble down the road. Thanks to Miguel Cornejo and his insights in HelloNation’s latest rundown, we get a clearer picture of...